Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.
about
'Striking the Right Balance' in Targeting PPARgamma in the Metabolic Syndrome: Novel Insights from Human Genetic StudiesEfficacy of pioglitazone on glycemic control and carotid intima-media thickness in type 2 diabetes patients with inadequate insulin therapyRegulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated ReceptorsPioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.PPAR gamma and human metabolic diseasePharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?Peroxisome proliferator-activated receptor-γ regulates inflammation and renin-angiotensin system activity in the hypothalamic paraventricular nucleus and ameliorates peripheral manifestations of heart failure.Inpatient management of hospitalized patients with type 2 diabetes.Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized PatientsAvandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.PPARgamma in human and mouse physiologyCharacterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells.Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.Thiazolidinediones and insulin: rationale for use and role of combination therapy in type 2 diabetes mellitus.Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.PPAR-gamma agonists and diabetic nephropathy.Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.Recent findings concerning thiazolidinediones in the treatment of diabetes.Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin SensitizerGlitazones in the treatment of cardiovascular risk factors.Measuring biomarkers to assess the therapeutic effects of PPAR agonists?Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case studyOptimizing combination treatment in the management of type 2 diabetesIdentification of PPARγ ligands with One-dimensional Drug Profile Matching.Role of renal proximal tubule transport in thiazolidinedione-induced volume expansion.Beyond the classic angiotensin-receptor-blocker profile.Reliability and feasibility of methods to quantitatively assess peripheral edemaNutrigenomic Functions of PPARs in Obesogenic Environments.In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion.Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes.LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.PPARs: diverse regulators in energy metabolism and metabolic diseases.Pioglitazone: side effect and safety profile.Discovery and development of selective PPAR gamma modulators as safe and effective antidiabetic agents.Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.Latest research and development trends in non-insulin anti-diabetics.
P2860
Q28221639-708F1228-189C-4060-B827-D975F4AE32A2Q33558402-DCE7D6CD-3FC9-4B87-93C5-A32C2EB3EB6AQ33960919-06DFCAA7-3EC8-4038-88CC-1F27AD70D9BFQ34260759-00580A0C-14A1-49CF-A629-DA9DFE0D4539Q34416432-32BF4C33-4C7D-4198-B06B-3116288E9F50Q34618210-2194D5BA-A7AF-4C60-97D1-6F6AC944A35FQ35688221-F012E4DA-6939-42FD-84AC-8379294D97EAQ35696867-01AB7503-4C68-48EB-B6D1-510CC1C6D034Q35907233-EBFC8CC6-76C8-4B76-8ABF-0BFF1894F8FAQ35912987-D350CB6F-4FCA-4C9B-AF70-69A79D79376FQ35941128-37DB61D9-CE17-4484-BCC8-EB037D3017AFQ36063081-F392FE1A-ADC2-4CF7-B84E-67016F87EF6BQ36128458-22254C1F-3765-4E52-AD13-64EFA6D7439AQ36182173-CD9C3CF9-268E-401A-BC56-519FFC877CF2Q36212207-CC8F7150-5B76-4C37-BA0A-69CE68AA0DA2Q36283822-F8D7529F-510F-4864-85DD-DF8024A466B5Q36326399-07AACF63-378B-44F9-893F-183F759249DBQ36350528-22537FFE-EF2E-42CD-8AA2-DA72BE71C1DBQ36407304-4CE465B9-3F89-4844-8BA0-5DD8365026FAQ36512559-275CF676-0499-4BB0-AFDB-3602843C99A7Q36765350-EEBB5642-4E82-4B3F-B7E2-B95D5302FBDDQ36849023-383B465D-1EB0-4970-99DF-3088CDF0AC8BQ37000780-84F0285A-23BA-441B-975B-5F1A795BC4AEQ37012012-A869180A-7C4B-48F2-A42E-D5B6F251851BQ37016305-4A71AD0A-E829-4E53-A9D5-6DEB40128206Q37019843-A80AAC16-3E44-49C2-A5B1-31FD0E03E6FFQ37031367-ECCBA39A-960C-4967-BC3D-37F04561828DQ37165170-5175C001-A69B-461E-84E9-ACCF43B4F808Q37195401-8A6E1B93-1503-4C8D-BF51-6B2A54CC27B5Q37200544-76C9734E-6DEB-4F17-8632-3E0E5B1CD067Q37249238-E0FEC22D-848E-4C21-9CA7-8F5879F211EEQ37500797-1995C4AD-BF3A-4AFA-AA51-FED2F9388F03Q37577126-019945B1-B8CE-4A7A-930D-F2B4EED3FF60Q37599904-127785E9-F2A6-4442-82D5-9C682675A5FAQ37622614-0CD3BD99-E620-4990-9410-561EF3D025BFQ37681306-490147DD-E3D7-4977-9467-41E8A6B6A228Q37696508-1784398E-E5DB-46AB-9D18-CF9E6088B992Q37724195-90858037-9176-4AA6-B298-B46483599C52Q37992593-D6EED909-3F73-49A1-B460-A324B9457C12Q38080471-7D90799A-2CC0-431F-A541-3C4694B3053E
P2860
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Thiazolidinediones, peripheral ...... gy, and clinical implications.
@ast
Thiazolidinediones, peripheral ...... gy, and clinical implications.
@en
type
label
Thiazolidinediones, peripheral ...... gy, and clinical implications.
@ast
Thiazolidinediones, peripheral ...... gy, and clinical implications.
@en
prefLabel
Thiazolidinediones, peripheral ...... gy, and clinical implications.
@ast
Thiazolidinediones, peripheral ...... gy, and clinical implications.
@en
P2093
P356
P1433
P1476
Thiazolidinediones, peripheral ...... gy, and clinical implications.
@en
P2093
Anna R Chang
Robert R Henry
Sunder Mudaliar
P304
P356
10.4158/EP.9.5.406
P577
2003-09-01T00:00:00Z